ArticlePhysiological reports2026
Ponatinib confers adult human cardiomyocyte toxicity via inhibition of AKT signaling.
Article in Physiological reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
As a widely used anticancer drug for the treatment of chronic myeloid leukemia, ponatinib is known to cause severe cardiovascular toxicities. Cardiomyocytes are the major functional units in the myocardium, and impairment of their viability and function plays a crucial role in cardiotoxic responses. Previous studies have indicated direct toxicity of ponatinib on cardiomyocytes, but the effect of ponatinib on adult human primary cardiomyocytes (hPCMs) remains unknown, largely due to sample scarcity and the technical challenges associated with the adult human cardiomyocyte model. Based upon our previous work establishing hPCMs as a pharmacologically competent model, we tested the direct toxicity of ponatinib on these cells. We reveal suppression of AKT, but not ERK, phosphorylation upon ponatinib treatment. Treatment of hPCMs with AKT inhibitor MK-2206 phenocopied ponatinib, while restoration of AKT signaling with UCL-TRO-1938 or insulin partially rescued hPCMs from cell death, suggesting a potential protective effect.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.